AU2011274537B9 - Adenovirus Ad36 E4orf1 protein for prevention and treatment of non-alcoholic fatty liver disease - Google Patents

Adenovirus Ad36 E4orf1 protein for prevention and treatment of non-alcoholic fatty liver disease Download PDF

Info

Publication number
AU2011274537B9
AU2011274537B9 AU2011274537A AU2011274537A AU2011274537B9 AU 2011274537 B9 AU2011274537 B9 AU 2011274537B9 AU 2011274537 A AU2011274537 A AU 2011274537A AU 2011274537 A AU2011274537 A AU 2011274537A AU 2011274537 B9 AU2011274537 B9 AU 2011274537B9
Authority
AU
Australia
Prior art keywords
seq
protein
functional variant
e4orfl
individual
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2011274537A
Other languages
English (en)
Other versions
AU2011274537A1 (en
AU2011274537B2 (en
Inventor
Nikhil Dhurandhar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Louisiana State University
Original Assignee
Louisiana State University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Louisiana State University filed Critical Louisiana State University
Publication of AU2011274537A1 publication Critical patent/AU2011274537A1/en
Application granted granted Critical
Publication of AU2011274537B2 publication Critical patent/AU2011274537B2/en
Publication of AU2011274537B9 publication Critical patent/AU2011274537B9/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10333—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2011274537A 2010-07-08 2011-07-08 Adenovirus Ad36 E4orf1 protein for prevention and treatment of non-alcoholic fatty liver disease Ceased AU2011274537B9 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36244310P 2010-07-08 2010-07-08
US61/362,443 2010-07-08
PCT/US2011/043338 WO2012006512A1 (en) 2010-07-08 2011-07-08 Adenovirus ad36 e4orf1 protein for prevention and treatment of non-alcoholic fatty liver disease

Publications (3)

Publication Number Publication Date
AU2011274537A1 AU2011274537A1 (en) 2013-02-14
AU2011274537B2 AU2011274537B2 (en) 2016-12-15
AU2011274537B9 true AU2011274537B9 (en) 2017-02-23

Family

ID=44629893

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2011274537A Ceased AU2011274537B9 (en) 2010-07-08 2011-07-08 Adenovirus Ad36 E4orf1 protein for prevention and treatment of non-alcoholic fatty liver disease

Country Status (11)

Country Link
US (2) US8951980B2 (enExample)
EP (1) EP2590665B1 (enExample)
JP (1) JP5965397B2 (enExample)
KR (1) KR101831638B1 (enExample)
CN (1) CN103052397B (enExample)
AU (1) AU2011274537B9 (enExample)
CA (1) CA2803787C (enExample)
ES (1) ES2550962T3 (enExample)
NZ (1) NZ606236A (enExample)
TW (1) TWI531650B (enExample)
WO (1) WO2012006512A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014062794A1 (en) 2012-10-17 2014-04-24 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Compositions and methods for improving glucose uptake
US9354963B2 (en) * 2014-02-26 2016-05-31 Microsoft Technology Licensing, Llc Service metric analysis from structured logging schema of usage data
US10047107B2 (en) 2014-04-23 2018-08-14 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Small molecule analogs of E4orf1
GB201910299D0 (en) * 2019-07-18 2019-09-04 Aouadi Myriam Medical uses, methods and uses

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602004004775T2 (de) * 2004-08-12 2007-11-22 Roche Diagnostics Gmbh Verfahren zur Diagnose von Leberfibrose.
US20060045919A1 (en) 2004-08-27 2006-03-02 Samueli Institute Homeopathic compositions and methods for the treatment of cancer
JP2008105945A (ja) * 2005-02-07 2008-05-08 Ajinomoto Co Inc アディポネクチンの分泌促進又は誘導作用を有するアシルアミド化合物
ES2472325T3 (es) * 2005-11-30 2014-06-30 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Gen y proteína del adenovirus 36 E4 orf 1 y sus usos
WO2007120362A2 (en) * 2005-12-27 2007-10-25 Obetech, Llc Adipogenic adenoviruses as a biomarker for disease
JP2008273938A (ja) * 2007-03-30 2008-11-13 Shiseido Co Ltd アディポネクチン産生促進剤

Also Published As

Publication number Publication date
KR20130100262A (ko) 2013-09-10
JP5965397B2 (ja) 2016-08-03
JP2013531681A (ja) 2013-08-08
AU2011274537A1 (en) 2013-02-14
KR101831638B1 (ko) 2018-02-23
TWI531650B (zh) 2016-05-01
NZ606236A (en) 2014-09-26
CN103052397B (zh) 2017-09-19
WO2012006512A1 (en) 2012-01-12
EP2590665A1 (en) 2013-05-15
CA2803787A1 (en) 2012-01-12
US20170340699A1 (en) 2017-11-30
TW201217529A (en) 2012-05-01
CA2803787C (en) 2018-12-04
AU2011274537B2 (en) 2016-12-15
HK1185261A1 (en) 2014-02-14
US20120027845A1 (en) 2012-02-02
ES2550962T3 (es) 2015-11-13
EP2590665B1 (en) 2015-09-16
US8951980B2 (en) 2015-02-10
CN103052397A (zh) 2013-04-17

Similar Documents

Publication Publication Date Title
Badmus et al. Molecular mechanisms of metabolic associated fatty liver disease (MAFLD): functional analysis of lipid metabolism pathways
Ma et al. Indole alleviates diet‐induced hepatic steatosis and inflammation in a manner involving myeloid cell 6‐Phosphofructo‐2‐kinase/Fructose‐2, 6‐Biphosphatase 3
Krishnapuram et al. Template to improve glycemic control without reducing adiposity or dietary fat
Tomita et al. Hepatic AdipoR2 signaling plays a protective role against progression of nonalcoholic steatohepatitis in mice
JP5767314B2 (ja) Ｆｇｆを用いて代謝障害を処置するための方法
Park et al. Lactobacillus rhamnosus GG improves glucose tolerance through alleviating ER stress and suppressing macrophage activation in db/db mice
Domingues et al. Antioxidant-upregulated mesenchymal stem cells reduce inflammation and improve fatty liver disease in diet-induced obesity
US20080112932A1 (en) Methods and reagents for the enhancement of virus transduction in the bladder epithelium
Huang et al. Hot-water extract of ripened Pu-erh tea attenuates DSS-induced colitis through modulation of the NF-κB and HIF-1α signaling pathways in mice
Guo et al. Adiponectin retards the progression of diabetic nephropathy in db/db mice by counteracting angiotensin II
AU2011274537B2 (en) Adenovirus Ad36 E4orf1 protein for prevention and treatment of non-alcoholic fatty liver disease
US20250320265A1 (en) Brown fat-selective adipokines
Li et al. Adenovirus-mediated overexpression of sST2 attenuates cardiac injury in the rat with severe acute pancreatitis
EP1954131B1 (en) Adenovirus 36 e4 orf 1 gene and protein and their uses
HK1185261B (en) Adenovirus ad36 e4orf1 protein for prevention and treatment of non-alcoholic fatty liver disease
WO2018028433A1 (zh) Creg蛋白用于预防或治疗体重超重、肥胖及其相关疾病的医药用途
Wang et al. Effects of adenovirus‐mediated liver‐selective overexpression of protein tyrosine phosphatase‐1b on insulin sensitivity in vivo
RU2409590C2 (ru) Новый пептид, участвующий в энергетическом гомеостазе
Kiyama et al. Reduction of fibrosis in a rat model of non‐alcoholic steatohepatitis cirrhosis by human HGF gene transfection using electroporation
Cefalu et al. Template to improve glycemic control without
CN121971588A (zh) Tas2r14调控adamts1在治疗胰岛素抵抗中的应用
US20120269796A1 (en) Method for Enhancing Pancreatic Beta Cell Proliferation, Increasing Serum Insulin Concentration, Decreasing Blood Glucose Concentration And Treating And/Or Preventing Diabetes
Xu et al. Targeting Hyaluronic Acid Synthase-3 (HAS3) for the Treatment of Advanced Renal Cell Carcinoma
Shimony et al. Pancreatic acinar and islet cell infection by low-dose SV40 administration
WO2017195901A1 (ja) 肝分泌型代謝制御因子阻害作用による肥満関連疾患治療剤

Legal Events

Date Code Title Description
SREP Specification republished
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired